Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib
The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L8...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221300712300148X |
| _version_ | 1797238061430472704 |
|---|---|
| author | Zihan Zhou Jie Huang Ming Ding Jing Huang Ting Wu Qun Wang Shuhua Han Yuan Lu |
| author_facet | Zihan Zhou Jie Huang Ming Ding Jing Huang Ting Wu Qun Wang Shuhua Han Yuan Lu |
| author_sort | Zihan Zhou |
| collection | DOAJ |
| description | The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L861Q often resulted in a lack of response to the first and third generation of EGFR TKIs. In this study, we reported a 64-year-old female patient, who initially presented with symptoms of pneumonia and showed positive response to anti-infection treatment, eventually diagnosed with stage Ⅳ lung adenocarcinoma (LUAD) harboring a rare EGFR G719X and L861Q compound mutations. The patient received 40 mg/day of afatinib and experienced no severe adverse events. As a result, partial response (PR) was observed based on CT scan and a progression free survival of 24 month was achieved. Her follow-up is still ongoing. The results of the present case support the effectiveness and safety of afatinib in LUAD patients carrying EGFR G719X and L861Q compound mutations. |
| first_indexed | 2024-04-24T17:29:39Z |
| format | Article |
| id | doaj.art-aee6ad8bab2547aba999dfce7d3acc01 |
| institution | Directory Open Access Journal |
| issn | 2213-0071 |
| language | English |
| last_indexed | 2024-04-24T17:29:39Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj.art-aee6ad8bab2547aba999dfce7d3acc012024-03-28T06:37:46ZengElsevierRespiratory Medicine Case Reports2213-00712024-01-0148101953Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using AfatinibZihan Zhou0Jie Huang1Ming Ding2Jing Huang3Ting Wu4Qun Wang5Shuhua Han6Yuan Lu7Department of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China; Medicine Department of Southeast University, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, ChinaDepartment of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China; Corresponding author.Department of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China; Corresponding author.The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L861Q often resulted in a lack of response to the first and third generation of EGFR TKIs. In this study, we reported a 64-year-old female patient, who initially presented with symptoms of pneumonia and showed positive response to anti-infection treatment, eventually diagnosed with stage Ⅳ lung adenocarcinoma (LUAD) harboring a rare EGFR G719X and L861Q compound mutations. The patient received 40 mg/day of afatinib and experienced no severe adverse events. As a result, partial response (PR) was observed based on CT scan and a progression free survival of 24 month was achieved. Her follow-up is still ongoing. The results of the present case support the effectiveness and safety of afatinib in LUAD patients carrying EGFR G719X and L861Q compound mutations.http://www.sciencedirect.com/science/article/pii/S221300712300148XEpidermal growth factor receptor (EGFR)Non-small cell lung cancer (NSCLC)AfatinibL861QG719XCompound mutations |
| spellingShingle | Zihan Zhou Jie Huang Ming Ding Jing Huang Ting Wu Qun Wang Shuhua Han Yuan Lu Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib Respiratory Medicine Case Reports Epidermal growth factor receptor (EGFR) Non-small cell lung cancer (NSCLC) Afatinib L861Q G719X Compound mutations |
| title | Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib |
| title_full | Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib |
| title_fullStr | Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib |
| title_full_unstemmed | Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib |
| title_short | Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib |
| title_sort | successful treatment of a patient with nsclc carrying uncommon compound l861q g719x epidermal growth factor receptor mutations using afatinib |
| topic | Epidermal growth factor receptor (EGFR) Non-small cell lung cancer (NSCLC) Afatinib L861Q G719X Compound mutations |
| url | http://www.sciencedirect.com/science/article/pii/S221300712300148X |
| work_keys_str_mv | AT zihanzhou successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT jiehuang successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT mingding successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT jinghuang successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT tingwu successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT qunwang successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT shuhuahan successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib AT yuanlu successfultreatmentofapatientwithnsclccarryinguncommoncompoundl861qg719xepidermalgrowthfactorreceptormutationsusingafatinib |